1. Ushio, J. et al. Pancreatic ductal adenocarcinoma: Epidemiology and risk factors. Diagnostics 11, 562 (2021).
2. Park, W., Chawla, A. & O’Reilly, E. M. Pancreatic cancer: A review. JAMA 326, 851–862 (2021).
3. Farkona, S., Diamandis, E. P. & Blasutig, I. M. Cancer immunotherapy: The beginning of the end of cancer?. BMC Med. 14, 73
(2016).
4. Balachandran, V. P., Beatty, G. L. & Dougan, S. K. Broadening the impact of immunotherapy to pancreatic cancer: Challenges and
opportunities. Gastroenterology 156, 2056–2072 (2019).
5. Skelton, R. A., Javed, A., Zheng, L. & He, J. Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. J.
Surg. Oncol. 116, 55–62 (2017).
6. Pommier, A. et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases.
Science 360, eaao4908 (2018).
Scientific Reports |
Vol:.(1234567890)
(2022) 12:21570 |
https://doi.org/10.1038/s41598-022-25065-w
12
www.nature.com/scientificreports/
7. Kunk, P. R., Bauer, T. W., Slingluff, C. L. & Rahma, O. E. From bench to bedside a comprehensive review of pancreatic cancer
immunotherapy. J. Immunother. Cancer 4, 14 (2016).
8. Merika, E. E., Syrigos, K. N. & Saif, M. W. Desmoplasia in pancreatic cancer. Can we fight it?. Gastroenterol. Res. Pract. 2012, 1–10
(2012).
9. Saka, D. et al. Mechanisms of T-cell exhaustion in pancreatic cancer. Cancers 12, 2274 (2020).
10. Bian, J. & Almhanna, K. Pancreatic cancer and immune checkpoint inhibitors—still a long way to go. Transl. Gastroenterol. Hepatol.
6, 6 (2021).
11. Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug
Discov. 18, 689–706 (2019).
12. Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: A new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14,
642–662 (2015).
13. Ushijima, Y. et al. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10,
a potential oncolytic virus. Microb. Infect. 9, 142–149 (2007).
14. Eissa, I. R. et al. Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and
clinical trials. Front. Oncol. 7, 149 (2017).
15. Mori, I. et al. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against
lethal challenge with HSV types 1 and 2. Microb. Infect. 7, 1492–1500 (2005).
16. Eissa, I. R. et al. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8 PD-1—tumor-infiltrating
T cells in PD-L1-enriched tumor microenvironment. Int. J. Cancer 149, 214–227 (2021).
17. Miyajima, N. et al. S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Nagoya J. Med. Sci. 83, 683 (2021).
18. Hashimoto, Y. et al. Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination
with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer. Ann. Oncol. 30, v269–v270 (2019).
19. Wu, Z. et al. Combination of cetuximab and oncolytic virus canerpaturev synergistically inhibits human colorectal cancer growth.
Mol. Therapy-Oncol. 13, 107–115 (2019).
20. Tan, T. G. et al. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of
human breast carcinoma xenograft. Int. J. Cancer 136, 1718–1730 (2015).
21. DeCensi, A. et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev. Res. 3,
1451–1461 (2010).
22. Sadeghi, N., Abbruzzese, J. L., Yeung, S. J., Hassan, M. & Li, D. Metformin use is associated with better survival of diabetic patients
with pancreatic cancer. Clin. Cancer Res. 18, 2905–2912 (2012).
23. Pollak, M. N. Investigating metformin for cancer prevention and treatment: The end of the beginning. Cancer Discov. 2, 778–790
(2012).
24. Wu, Z., Zhang, C. & Najafi, M. Targeting of the tumor immune microenvironment by metformin. J. Cell Commun. Signal. 16,
333–348 (2022).
25. Eikawa, S. et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc. Natl. Acad. Sci. 112, 1809–1814
(2015).
26. Kunisada, Y. et al. Attenuation of CD4 CD25 regulatory T cells in the tumor microenvironment by metformin, a type 2 diabetes
drug. EBioMedicine 25, 154–164 (2017).
27. Xu, P. et al. Metformin inhibits the function of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Biomed.
Pharmacother. 120, 109458 (2019).
28. Uehara, T. et al. Metformin induces CD11b -cell-mediated growth inhibition of an osteosarcoma: Implications for metabolic
reprogramming of myeloid cells and anti-tumor effects. Int. Immunol. 31, 187–198 (2019).
29. Ding, L. et al. Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget 6, 36441 (2015).
30. Kumar, A., Chamoto, K., Chowdhury, P. S. & Honjo, T. Tumors attenuating the mitochondrial activity in T cells escape from PD-1
blockade therapy. Elife 9, e52330 (2020).
31. Elgendy, M. et al. Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating
the PP2A-GSK3β-MCL-1 axis. Cancer Cell 35, 798–815 (2019).
32. Ishihara, M. et al. Systemic CD8 T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus
with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor. PLoS ONE 9, e104669
(2014).
33. Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4 T cells in cancer immunotherapy—new insights into old
paradigms. Cancer Gene Ther. 28, 5–17 (2021).
34. Reiser, J. & Banerjee, A. Effector, memory, and dysfunctional CD8 T cell fates in the antitumor immune response. J. Immunol. Res.
2016, 1–14 (2016).
35. Hensel, J. et al. 179 CD8+CD69+ expanded tumor infiltrating lymphocytes from soft tissue sarcoma have increased tumor-specific
functional capacity. J. Immunother. Cancer 9, 217 (2021).
36. Cancel, J., Crozat, K., Dalod, M. & Mattiuz, R. Are conventional type 1 dendritic cells critical for protective antitumor immunity
and how?. Front. Immunol. 10, 9 (2019).
37. Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell
immunity. Cancer Cell 26, 638–652 (2014).
38. Bachem, A. et al. Expression of XCR1 characterizes the Batf3-dependent lineage of dendritic cells capable of antigen crosspresentation. Front. Immunol. 3, 214 (2012).
39. Crozat, K. et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8α
dendritic cells. J. Exp. Med. 207, 1283–1292 (2010).
40. Dorner, B. G. et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8 T cells. Immunity 31, 823–833 (2009).
41. Morimoto, D. et al. C-REV retains high infectivity regardless of the expression levels of cGAS and STING in cultured pancreatic
cancer cells. Cells 10, 1502 (2021).
42. Chandel, N. S. et al. Are metformin doses used in murine cancer models clinically relevant?. Cell Metab. 23, 569–570 (2016).
43. Ma, M. et al. Low glucose enhanced metformin’s inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing
energy stress via up-regulation of miR-210-5p. Cell Cycle 19, 2168–2181 (2020).
44. Hotta, Y. et al. Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity. Oncol. Virotherapy
6, 31 (2017).
45. Nishida, M. et al. Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/
mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes. J. Immunother. Cancer 9(9), e002954 (2021).
46. Chung, Y. M. et al. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8 T cells via pharmacological activation of
FOXO3. J. Immunother. Cancer 9(12), e002772 (2021).
47. Paul, M. S. & Ohashi, P. S. The roles of CD8 T cell subsets in antitumor immunity. Trends Cell Biol. 30, 695–704 (2020).
Scientific Reports |
(2022) 12:21570 |
https://doi.org/10.1038/s41598-022-25065-w
13
Vol.:(0123456789)
www.nature.com/scientificreports/
48. Reome, J. B., Hylind, J. C., Dutton, R. W. & Dobrzanski, M. J. Type 1 and type 2 tumor infiltrating effector cell subpopulations in
progressive breast cancer. Clin. Immunol. 111, 69–81 (2004).
49. Fernandez-Poma, S. M. et al. Expansion of tumor-infiltrating CD8 T cells expressing PD-1 improves the efficacy of adoptive T-cell
therapy. Cancer Res. 77, 3672–3684 (2017).
50. Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8 T cells
in tumors. Immunity 54, 1561–1577 (2021).
51. Tanaka, A. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res. 27, 109–118 (2017).
52. Ring, E. K. et al. Newly characterized murine undifferentiated sarcoma models sensitive to virotherapy with oncolytic HSV-1
M002. Mol. Therapy-Oncol. 7, 27–36 (2017).
53. Kaufman, H. L. et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding
GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17, 718–730 (2010).
54. Joshi, N. S. et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity
43, 579–590 (2015).
55. Laidlaw, B. J. et al. Production of IL-10 by CD4 regulatory T cells during the resolution of infection promotes the maturation of
memory CD8 T cells. Nat. Immunol. 16, 871–879 (2015).
56. Laidlaw, B. J., Craft, J. E. & Kaech, S. M. The multifaceted role of CD4 T cells in CD8 T cell memory. Nat. Rev. Immunol. 16, 102–111
(2016).
57. Cheng, G. et al. IL-2 receptor signaling is essential for the development of Klrg1 terminally differentiated T regulatory cells. J.
Immunol. 189, 1780–1791 (2012).
58. Villadangos, J. A. & Schnorrer, P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev.
Immunol. 7, 543–555 (2007).
59. Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking
and adoptive T cell therapy. Cancer Cell 31, 711–723 (2017).
60. Gong, J., Sachdev, E., Mita, A. C. & Mita, M. M. Clinical development of reovirus for cancer therapy: An oncolytic virus with
immune-mediated antitumor activity. World J. Methodol. 6, 25 (2016).
61. Streby, K. A. et al. First-in-human intravenous Seprehvir in young cancer patients: A phase 1 clinical trial. Mol. Ther. 27, 1930–1938
(2019).
62. Shikano, T. et al. High therapeutic potential for systemic delivery of a liposome conjugated herpes simplex virus. Curr. Cancer
Drug Targets 11, 111–122 (2011).
63. Yoon, A. et al. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted
PAMAM-based dendrimer in orthotopic lung tumor model. J. Control. Release 231, 2–16 (2016).
64. Atasheva, S. et al. Systemic cancer therapy with engineered adenovirus that evades innate immunity. Sci. Transl. Med. 12, eabc6659
(2020).
65. Morrison, J. et al. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor
receptor. Mol. Ther. 16, 244–251 (2008).
66. Oh, C., Chon, H. J. & Kim, C. Combination immunotherapy using oncolytic virus for the treatment of advanced solid tumors. Int.
J. Mol. Sci. 21, 7743 (2020).
67. Zhang, Y. et al. Oncolytic adenovirus expressing ST13 increases antitumor effect of tumor necrosis factor-related apoptosis-inducing
ligand against pancreatic ductal adenocarcinoma. Hum. Gene Ther. 31, 891–903 (2020).
68. Todo, T. et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: A phase 2 trial. Nat. Med. 28,
1630–1639 (2022).
69. Kohlhapp, F. J. & Kaufman, H. L. Molecular pathways: Mechanism of action for talimogene laherparepvec, a new oncolytic virus
immunotherapy T-VEC for cancer. Clin. Cancer Res. 22, 1048–1054 (2016).
70. Zhu, Z. et al. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling
pathways. Mol. Cancer 21, 196 (2022).
71. Deng, J. et al. Novel application of metformin combined with targeted drugs on anticancer treatment. Cancer Sci. 110, 23–30
(2019).
72. Alzahrani, A. S. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Semin. Cancer Biol. 59, 125–132 (2019).
73. Fu, X., Tao, L., Rivera, A. & Zhang, X. Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that
are resistant to virus replication. Int. J. Cancer 129, 1503–1510 (2011).
74. Hunter, R. W. et al. Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nat. Med. 24,
1395–1406 (2018).
75. Ma, T. et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature 603, 159–165 (2022).
76. Memmott, R. M. et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. 3, 1066–1076 (2010).
77. Blagih, J. et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42, 41–54
(2015).
78. Cooper, L. A., Sina, B. J., Turell, M. J. & Scott, T. W. Effects of initial dose on eastern equine encephalomyelitis virus dependent
mortality in intrathoracically inoculated Culiseta melanura (Diptera: Culicidae). J. Med. Entomol. 37, 815–819 (2000).
79. Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines
IFN-γ and IL-12. Immunity 49, 1148–1161 (2018).
Acknowledgements
We are thankful to Prof. Yukihiro Nishiyama for the isolation of C-REV in the Department of Virology, Nagoya
University Graduate School of Medicine. M.A is supported by a full scholarship from the Japanese government.
M.A.A is supported by a full scholarship from the Ministry of Higher Education of the Arab Republic of Egypt.
We also thank Emi Uematsu, Yumiko Samizo and Yukiko Kohmura for their technical assistance.
Author contributions
Conceptualization: Y.N., H.K.; investigation: M.A., I.R.E., M.A.A.; project administration: H.K.; supervision:
Y.N., M.T., Y.K., H.K.; writing-original draft: M.A., M.A.A.; writing-review & editing: S.M., P.A.S., I.B.V. All
authors reviewed the manuscript.
Funding
Takara Bio, Inc.; Japan Grants-in-Aid for Scientific Research, Grant/Award Numbers: 16K15611, 16H05413.
Scientific Reports |
Vol:.(1234567890)
(2022) 12:21570 |
https://doi.org/10.1038/s41598-022-25065-w
14
www.nature.com/scientificreports/
Competing interests Maki Tanaka is an employee of Takara Bio, Inc. and Hideki Kasuya received research funding from Takara Bio,
Inc. The other authors declare no competing interests. Takara Bio, Inc. had no role in the conceptualization, or
design of the study, in the collection, analysis, or interpretation of data, in the writing of the article, or in the
decision to publish the article.
Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/
10.1038/s41598-022-25065-w.
Correspondence and requests for materials should be addressed to H.K.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2022
Scientific Reports |
(2022) 12:21570 |
https://doi.org/10.1038/s41598-022-25065-w
15
Vol.:(0123456789)
...
論文の公開元へ
